| Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial L Hansson, A Zanchetti, SG Carruthers, B Dahlöf, D Elmfeldt, S Julius, ... The Lancet 351 (9118), 1755-1762, 1998 | 8894 | 1998 |
| Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm ... European heart journal 31 (19), 2369-2429, 2010 | 8586 | 2010 |
| Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol B Dahlöf, RB Devereux, SE Kjeldsen, S Julius, G Beevers, U de Faire, ... The Lancet 359 (9311), 995-1003, 2002 | 7835 | 2002 |
| Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian … PS Sever, B Dahlöf, NR Poulter, H Wedel, G Beevers, M Caulfield, ... The Lancet 361 (9364), 1149-1158, 2003 | 5568 | 2003 |
| Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the … B Dahlöf, PS Sever, NR Poulter, H Wedel, DG Beevers, M Caulfield, ... The Lancet 366 (9489), 895-906, 2005 | 4721 | 2005 |
| Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients K Jamerson, MA Weber, GL Bakris, B Dahlöf, B Pitt, V Shi, A Hester, ... New England Journal of Medicine 359 (23), 2417-2428, 2008 | 3170 | 2008 |
| Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention … L Hansson, LH Lindholm, L Niskanen, J Lanke, T Hedner, A Niklason, ... The Lancet 353 (9153), 611-616, 1999 | 2813 | 1999 |
| Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension) B Dahlöf, L Hansson, LH Lindholm, B Schersten, T Ekbom, PO Wester The Lancet 338 (8778), 1281-1285, 1991 | 2662 | 1991 |
| Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against … LH Lindholm, H Ibsen, B Dahlöf, RB Devereux, G Beevers, U de Faire, ... The Lancet 359 (9311), 1004-1010, 2002 | 2340 | 2002 |
| Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study L Hansson, LH Lindholm, T Ekbom, B Dahlöf, J Lanke, B Scherstén, ... The Lancet 354 (9192), 1751-1756, 1999 | 2162 | 1999 |
| Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies B Dahlöf, K Pennert, L Hansson American journal of hypertension 5 (2), 95-110, 1992 | 1463 | 1992 |
| Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem … L Hansson, T Hedner, P Lund-Johansen, SE Kjeldsen, LH Lindholm, ... The Lancet 356 (9227), 359-365, 2000 | 1327 | 2000 |
| Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke RL Sacco, HC Diener, S Yusuf, D Cotton, S Ôunpuu, WA Lawton, ... New England Journal of Medicine 359 (12), 1238-1251, 2008 | 1261 | 2008 |
| Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in … K Wachtell, M Lehto, E Gerdts, MH Olsen, B Hornestam, B Dahlöf, H Ibsen, ... Journal of the American College of Cardiology 45 (5), 712-719, 2005 | 1251 | 2005 |
| Prognostic significance of left ventricular mass change during treatment of hypertension RB Devereux, K Wachtell, E Gerdts, K Boman, MS Nieminen, ... Jama 292 (19), 2350-2356, 2004 | 1128 | 2004 |
| Telmisartan to prevent recurrent stroke and cardiovascular events S Yusuf, HC Diener, RL Sacco, D Cotton, S Ôunpuu, WA Lawton, ... New England Journal of Medicine 359 (12), 1225-1237, 2008 | 1041 | 2008 |
| Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events PM Okin, RB Devereux, S Jern, SE Kjeldsen, S Julius, MS Nieminen, ... Jama 292 (19), 2343-2349, 2004 | 823 | 2004 |
| Effect of spironolactone on blood pressure in subjects with resistant hypertension N Chapman, J Dobson, S Wilson, B Dahlof, PS Sever, H Wedel, ... hypertension 49 (4), 839-845, 2007 | 820 | 2007 |
| Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study H Ibsen, MH Olsen, K Wachtell, K Borch-Johnsen, LH Lindholm, ... Hypertension 45 (2), 198-202, 2005 | 801 | 2005 |
| The impact of serum uric acid on cardiovascular outcomes in the LIFE study A Høieggen, MH Alderman, SE Kjeldsen, S Julius, RB Devereux, ... Kidney international 65 (3), 1041-1049, 2004 | 738 | 2004 |
